Hillhouse discloses 9.5% ArriVent BioPharma (AVBP) ownership stake

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. shareholder Hillhouse Investment Management, Ltd. reported beneficial ownership of 3,929,117 shares of ArriVent common stock, representing 9.5% of the company’s outstanding shares. This reflects Hillhouse’s position as of a reference base of 41,281,361 shares outstanding on November 7, 2025.

The shares are held through affiliated entities VI Holdings Limited, VIII Holdings Limited and ARVT Holdings Limited, for which Hillhouse is the sole management company. Hillhouse reports sole voting and dispositive power over all 3,929,117 shares, and the filing is an amendment to a prior Schedule 13G.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ArriVent BioPharma, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

04272N102

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 04272N102

1

Names of Reporting Persons

Hillhouse Investment Management, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,929,117.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,929,117.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,929,117.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ArriVent BioPharma, Inc.
(b)	Address of issuer's principal executive offices: 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PA, 19073-3269
Item 2.
(a)	Name of person filing: This statement is filed by: This Schedule 13G is filed by Hillhouse Investment Management, Ltd, an exempted Cayman Islands company ("HIM" or the "Reporting Person") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of ArriVent BioPharma, Inc. (the "Company") held by VSUM VI Holdings Limited ("VSUM VI"), VSUM VIII Holdings Limited ("VSUM VIII") and ARVT Holdings Limited ("ARVT"). HIM acts as the sole management company of each Hillhouse Venture Fund V, L.P. ("Venture Fund V"), Hillhouse Healthcare Fund, L.P. ("Healthcare Fund") and Hillhouse Venture Fund VI, L.P. ("Venture Fund VI"). VSUM VI is wholly owned by Venture Fund V; VSUM VIII is wholly owned by Healthcare Fund; and ARVT is wholly owned by Venture Fund VI. HIM is hereby deemed to be the beneficial owner of, and to control the voting power of, the Common Stock held by VSUM VI, VSUM VIII and ARVT.
(b)	Address or principal business office or, if none, residence: The address of the business office of the Reporting Person is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, KY1-9006.
(c)	Citizenship: Cayman Islands
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 04272N102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 41,281,361 shares of Common Stock outstanding as of November 7, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 10, 2025.
(b)	Percent of class: 9.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Hillhouse Investment Management, Ltd.

Signature:	/s/ Audrey Woon
Name/Title:	Audrey Woon, Chief Compliance Officer
Date:	02/17/2026

FAQ

What stake does Hillhouse Investment Management hold in ArriVent BioPharma (AVBP)?

Hillhouse Investment Management reports beneficial ownership of 3,929,117 ArriVent BioPharma common shares, equal to 9.5% of the outstanding stock. This percentage is based on 41,281,361 shares outstanding as of November 7, 2025, from ArriVent’s Form 10-Q.

How many ArriVent BioPharma (AVBP) shares does Hillhouse control voting for?

Hillhouse reports sole voting power over 3,929,117 ArriVent shares and no shared voting power. It also has sole dispositive power over the same number of shares, meaning it alone decides how these shares are voted and when they may be sold.

Through which entities does Hillhouse hold its ArriVent BioPharma (AVBP) shares?

The ArriVent BioPharma shares are held via VI Holdings Limited, VIII Holdings Limited and ARVT Holdings Limited. These entities are wholly owned by related Hillhouse funds, for which Hillhouse Investment Management, Ltd. serves as the sole management company, giving it beneficial ownership.

What type of SEC filing did Hillhouse submit for its ArriVent (AVBP) position?

Hillhouse filed an Amendment No. 1 to Schedule 13G, which is a beneficial ownership report for large shareholders. The amendment updates previously reported information about Hillhouse’s ownership of ArriVent BioPharma common stock and confirms its current 9.5% stake.

On what ownership base did Hillhouse calculate its 9.5% ArriVent (AVBP) stake?

The 9.5% ownership figure is calculated using 41,281,361 ArriVent common shares outstanding as of November 7, 2025. That outstanding share count comes from ArriVent’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.